ea0065p226 | Metabolism and Obesity | SFEBES2019
Bashir Bilal
, Bharaj Harnovdeep
, Hutchesson Andrew
, Banerjee Moulinath
Background and aims: Statins has long been used as first line treatment option for hypercholesterolemia however; half of population doesnt achieve target LDL reduction. Proprotein convertase subtilisin kexin 9 inhibitors (PCSK9i) are a promising addition to anti-dyslipidemic armamentarium. Aim of this study is to find out the efficacy of PCSK9 inhibitors in a district general hospital of Northwest of England.Method: We identified all the patient wh...